For example, Guebre-Egziabher et al. [43] noted decreased expression of metalloprotease 9 (MMP9) and CD68 in subcutaneous abdominal adipose tissue on a low not high dose of MaxEPA in a small number (n = 12) of individuals with chronic kidney disease (CKD) who were randomised to take either a low (n = 6) or high (n = 6) dose of MaxEPA for 10 weeks. The gene discussed is MMP9; the disease is chronic kidney disease.